KZIA

Kazia Therapeutics
KZIA
Market cap $19M

5.71 USD

+0.63

12.40%

At close Nov 19, 4:00 PM EST

After hours

5.35

-0.36

6.30%

1 day

12.40%

5 days

-10.64%

1 month

1.60%

3 months

50.66%

6 months

107.64%

Year to date

26.89%

1 year

-26.04%

5 years

-82.27%

10 years

-91.40%

About: Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Employees: 9

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,735 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

581% more capital invested

Capital invested by funds: $135K [Q2] → $922K (+$787K) [Q3]

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

64% more funds holding

Funds holding: 11 [Q2] → 18 (+7) [Q3]

0.52% more ownership

Funds ownership: 0.2% [Q2] → 0.72% (+0.52%) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for KZIA.

See Analyst Rankings

Financial journalist opinion

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM) Company updates to corporate presentation and participation in upcoming medical meetings SYDNEY , Nov. 4, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company in December 2024 to discuss the potential pathways to registration of Kazia's blood brain barrier penetrant PI3K/mTOR inhibitor, paxalisib, for the treatment of patients with newly diagnosed GBM. In July 2024, the Company announced results from the Phase II/III clinical trial, GBM-AGILE, in which newly diagnosed unmethylated patients with glioblastoma treated with paxalisib showed clinically meaningful improvement in a prespecified secondary analysis for overall survival.

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR) Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracranial response which compares favorably to historical response rates for whole brain radiation therapy alone SYDNEY , Oct. 2, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I study (NCT04192981) evaluating concurrent paxalisib and radiation therapy (RT) in patients for the treatment of solid tumor brain metastases (BM) or leptomeningeal metastases (LM) harboring PI3K pathway mutations at the American Society for Radiation Oncology 66th Annual Meeting (ASTRO 2024), which is taking place from September 29 - October 2, 2024, in Washington, D.C. "The encouraging response rates observed from this Phase 1 study suggests that the concurrent administration of the investigational brain penetrant PI3K inhibitor, paxalisib, in combination radiation therapy appears to be a viable treatment approach for addressing the tumor radioresistance in patients harboring PI3K pathway mutations," said John Friend, M.D.

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

SYDNEY , Sept. 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington.

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

SYDNEY , Sept. 12, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to obtain an exclusive license to certain intellectual property rights in relation to combination therapies consisting of PI3K inhibitor drugs, and one or more immunotherapy or PARP inhibitor drugs (PI3K combination).

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

Australian biotech company Kazia Therapeutics (NASDAQ: KZIA ) stock rocked the market after reporting encouraging results from a Phase II/III trial for its glioblastoma brain cancer therapy Paxalisib. The positive results extended the life of patients by over three months compared to the current standard of care.

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics

Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers?

Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics

Zacks Investment Research

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher

If you've read all the warnings and still want to jump into some of the top penny stocks to buy, focus on the key fundamentals. That includes its earnings numbers, business models, product pipelines and what market they're part of.

From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher

KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains

Kazia Therapeutics (NASDAQ: KZIA ) stock is continuing to rally on Thursday after the company reported positive alongside clinical trial data yesterday. The Kazia Therapeutics clinical trial covered the company's paxalisib as a treatment of glioblastoma.

KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains

See News Rankings

Charts implemented using Lightweight Charts™